Related Experiment Video
Updated: May 27, 2026
08:04
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition
1Department of Nephrology, Charité Universitätsmedizin Berlin, Germany. klemens.budde@charite.de
Summary
Tuberous sclerosis complex (TSC) causes tumors, especially kidney angiomyolipomas. mTOR inhibitors show promise for treating TSC by targeting the underlying mTOR pathway, offering a new therapeutic approach.
Area of Science:
- Nephrology
- Oncology
- Genetics
Background:
- Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by benign tumor development in multiple organs.
- Kidney angiomyolipomas in TSC patients are often bilateral, symptomatic, and pose a risk of life-threatening hemorrhage.
- TSC is linked to mutations in TSC1 or TSC2 genes, leading to hyperactive mammalian target of rapamycin (mTOR) signaling.
Purpose of the Study:
- To review the diagnosis and management of TSC-associated kidney angiomyolipomas.
- To explore the role of the mTOR pathway in TSC pathogenesis.
- To discuss the therapeutic potential of mTOR inhibitors for TSC.
Main Methods:
- Literature review of diagnostic and management strategies for TSC-associated angiomyolipomas.
- Analysis of preclinical and clinical studies on mTOR inhibitors in TSC.
- Exploration of the mTOR pathway's relevance in TSC pathogenesis.
Main Results:
- mTOR inhibitors have demonstrated efficacy in preclinical models of TSC, inhibiting tumor growth.
- Clinical studies indicate promising results for mTOR inhibitors in treating TSC-associated angiomyolipomas and subependymal giant cell astrocytomas.
- Current treatments focus on kidney function preservation and hemorrhage prevention.
Conclusions:
- mTOR pathway dysregulation is central to TSC pathogenesis.
- mTOR inhibitors represent a promising systemic therapy targeting the root cause of TSC.
- Further research into mTOR-inhibitor therapy could significantly improve TSC management.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:42Microtubule Associated Proteins (MAPs)
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...